Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) is hosting an event on May 23, 2022, in New York City to launch the Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This initiative aims to assess the impact of cancer on dogs using data from a Gallup survey and thousands of anonymized medical records. The event will feature presentations by veterinary experts and performances by Broadway stars, emphasizing the importance of canine cancer awareness. This launch coincides with the first annual National Canine Cancer Awareness Day.
Jaguar Health (NASDAQ:JAGX) announced an analyst report issued by TAG Investment Bankers, led by analyst Chris Wickham. This report, reflecting paid research, showcases Jaguar Health's capability in the biotechnology sector. The company, focused on developing plant-based medicines for gastrointestinal issues, holds a majority stake in Napo Therapeutics, an entity working to expand crofelemer access in Europe. The ongoing OnTarget study evaluates crofelemer for adult cancer patients to prevent diarrhea. Jaguar maintains a commitment to sustainable harvesting and developing innovative pharmaceutical solutions.
Jaguar Health (NASDAQ:JAGX) launched a telehealth program for its FDA-approved antidiarrheal drug Mytesi on May 6, 2022. This program aims to enhance patient access, especially for those suffering from HIV-related diarrhea. Patients can connect with healthcare providers using mobile devices at their convenience, eliminating long wait times for consultations. The telehealth service underscores the importance of immediate care in addressing sensitive health issues. Mytesi is intended for adults with noninfectious diarrhea related to HIV/AIDS receiving antiretroviral therapy.
Jaguar Health reported a net revenue of approximately $2.6 million for the first quarter of 2022, marking a 24% increase from the previous quarter and a 112% year-over-year growth. This revenue boost is attributed to the transition to a closed network of specialty pharmacies. The company is focused on ongoing clinical trials for crofelemer, particularly for cancer therapy-related diarrhea, with enrollment expected to complete in the first half of 2023. Future milestones include proof-of-concept studies for short bowel syndrome and congenital diarrheal disorders in 2022-2023.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of 50,000 restricted stock units (RSUs) to Mark Johnson, its newly appointed Senior Vice President of Product Development, effective May 6, 2022. The RSUs will fully vest on the one-year anniversary of his hire, contingent on his continued service with the company. The compensation, approved by the Compensation Committee, serves as an inducement for his acceptance of the position. Jaguar, a commercial-stage pharmaceuticals company, focuses on developing plant-based medications for gastrointestinal distress in humans and animals.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM ET to discuss first-quarter 2022 financial results and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending March 31, 2022. The previous release incorrectly stated the date as March 10. Jaguar Health focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal distress in humans and animals. For more details, register here.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM Eastern Time to discuss first-quarter 2022 financial results and corporate updates. The earnings report will be filed on May 10, 2022, on Form 10-Q. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues in both humans and animals. The company is known for its drug candidate, crofelemer, which is currently involved in a pivotal Phase 3 clinical trial for diarrhea in cancer patients receiving targeted therapy.
Jaguar Health (NASDAQ:JAGX) has filed the final regulatory section with the FDA for conditional approval of its oral plant-based drug Canalevia to treat exercise-induced diarrhea (EID) in dogs. Canalevia would be the first treatment for EID in dogs to gain any form of FDA approval. Following conditional approval for chemotherapy-induced diarrhea (CID) in December 2021, Jaguar expects EID approval by Q4 2022. The FDA has confirmed the completeness of three of the four required technical sections for this application.
Jaguar Health (NASDAQ:JAGX) announced the commercial availability of Canalevia-CA1, the first FDA-approved treatment for chemotherapy-induced diarrhea (CID) in dogs. Following its conditional approval on December 21, 2021, this oral medication is now accessible through leading veterinary distributors in the U.S. The company highlights the unmet need for such a treatment, as over half of surveyed veterinarians noted CID disrupts cancer treatment in dogs. Canalevia-CA1, using the plant-based active ingredient crofelemer, aims to enhance dogs' comfort during chemotherapy.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that its CEO, Lisa Conte, will present at NobleCon18 on April 21, 2022, at 11:00 AM Eastern at the Hard Rock Hotel & Casino in Hollywood, Florida. Attendees can meet management during a breakout session at 10:00 AM. Registration for this investor conference is free via the provided link. A video of the presentation will be available the next day on Noble Capital Markets' website and archived for 90 days. Jaguar focuses on sustainable, plant-based medicines for gastrointestinal issues.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
